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Abstract 
 
 The advent of electronic health records (EHR) and clinical decision support (CDS) has 
brought numerous changes in the healthcare field and has improved how patients receive care. 
The field of pharmacogenomics has made many breakthrough discoveries in the last few decades 
and these new advances have immensely reduced the cost of genetic testing. As advances have 
been made, researchers have discovered that individuals may respond to a medication differently 
due to genetic variants. There is a shift in the medical field from a one size fits all model to a 
personalized medicine model based on genetic information. Institutions have started to 
incorporate genetic information in their EHR and CDS systems to aid clinicians in the 
prescribing process. The rate of implementation is uneven among the institutions across the 
United States. Healthcare institutions have encountered some challenges associated with 
implementing pharmacogenomic data into CDS and EHR system. These challenges include lack 
of clinician education about pharmacogenomic data, poor user interface, and lack of resources 
for additional information for these alerts. If these challenges are overcome, there is great 
potential for pharmacogenomic CDS systems to help improve patient care and reduce adverse 
drug events.   
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Implementation of Pharmacy Informatics 
 
Chapter 1 
 
Introduction 
 
Health informatics has rapidly advanced in the last several decades and there has been 
tremendous growth in the field. The U.S. National Library of Medicine as define health 
informatics as an “interdisciplinary study of the design, development, adoption, and application 
of IT-based innovations in healthcare services delivery, management, and planning” (HIMSS, 
2014). There are several subdivisions of health informatics such as pharmacy informatics and 
nursing informatics. Health informatics and associated fields are currently being utilized in a 
variety of ways to provide a high level of patient care and improve outcomes. For example, a 
large number of hospitals in the United States now utilize automated dispensing cabinets to 
dispense medications in inpatient and outpatient pharmacies. The utilization of computerized 
physician order entry (CPOE) system is also on the rise. These systems and many other systems 
like it require health informatics to utilize them to their full potential. 
Background of Problem 
 
Numerous new technologies have been introduced in the healthcare field, and there has 
been a shift in the healthcare world from a “one size fits all model to a precision personalized 
regimen” (Klein, 2017). The Human Genome Project, which was conducted to map and 
understand all of the genes of human beings, gave researchers an insight into human genetic 
information (NIH, 2018). As technology and science advanced, over the years, scientists 
discovered that some medications effect patients differently. Advancements in genetics research 
revealed that patients metabolize medications differently based on their genetic makeup. A 
medication that has gone through rigorous clinical trials can still cause adverse drug reactions 
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(ADRs) in a certain patient population. These varying responses to drugs are typically due to 
genetic variations. There are two types of genetics variations, inherited variants and acquired 
variants (Ko, 2016).  The inherited variants that encode drug-metabolizing enzymes, drug 
transporters, drug targets, and human-leukocyte antigen (HLA) can affect individual response to 
medication can impact how individual patients respond to certain medications. The acquired 
mutations are associated with the development or progression, and they can “affect the drug 
response of tumors that carry specific mutations, so called target therapy” (Ko, 2016). 
Pharmacogenomics is the utilization of “current technology for precise determination of genetic 
variants influence drug response, and to develop personalized strategies that maximize 
therapeutic efficacy and assure drug safety” (Ko, 2016). Many large-scale genome-wide studies 
have helped increase our understanding of the underlying mechanism of drug efficacy and 
ADRs. Pharmacogenomics “is the driving force behind” the precision medication therapeutic 
approach (Klein, 2017). Clinicians can utilize pharmacogenomics data to improve the clinical 
outcomes of pharmacotherapy. For example, warfarin, which is an anticoagulation medication, 
has been observed to be altered by two different genetic variations. Clinicians can utilize the 
genetic information of a patient in regards to warfarin dosing to improve the initial dosing of the 
medication and ensure that the patient does not have bleeding complications due to this 
medication. Patient genetic data can be utilized to improve prescribing practices for many other 
medications. The adoption and implementation of pharmacogenomics has been slow in 
institutions in the United States. Pharmacogenomics can help decrease healthcare costs by 
decreasing the number of adverse drug reactions and improve patient care by potentially 
allowing providers to prescribe medications with a patient’s genetic data in mind. 
Purpose of the Study 
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 Various advances have been made in the informatics field as well as the 
pharmacogenomics field. Many healthcare organizations in the United States are obtaining 
genetic information and utilizing that information in various ways. Some electronic health record 
(EHR) systems are capable of integrating genomic data and using clinical decision support 
(CDS) systems, however, there are many institutions that have not begun integrating genetic 
information into an EHR system or the EHR system is not capable of integrating the genomic 
data. The number of institutions utilizing pharmacogenomics data is increasing, however, their 
approach to implementation of pharmacogenomics data varies across the board. The adoption of 
pharmacogenomic CDS system integrated into an EHR system is currently largely limited to 
large academic centers. The purpose of this study is to summarize the literature describing 
implementation and utilization of pharmacogenomic information into electronic health records 
and clinical decision support. 
Significance of the Study 
 As advances in medications and pharmacogenomics occur, there will be a shift from a 
one size fits all to a personalized medication approach. Healthcare institutions are moving 
towards utilizing genomic data to provide better patient care. There are some institutions that are 
currently utilizing pharmacogenomic information when prescribing certain medications, 
however, the number of institutions implementing pharmacogenomic information into EHR and 
CDS will increase over the years. For example, in oncology, genomic data is becoming 
important for prescribing a treatment regimen because certain cancers respond to specific 
treatments if they have that genomic variation, or the cancer may not respond to certain therapies 
because of the variation. The genomic data of these patients needs to be incorporated into the 
EHR system to allow clinicians to make appropriate decisions for their patients and provide 
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better patient care. These advancements will aid in providing high-quality of care to patients. 
Research Questions 
The objective of this paper is to determine how pharmacogenomics data is being implemented 
into EHR and CDS systems. How are institutions implementing pharmacogenomic data into their 
EHR and CDS systems? How is this implementation changing prescribing practice? 
Definition of Terms 
Electronic Health Records (EHR) – an electronic version of a patient’s paper chart which 
includes diagnosis, medication history, treatment histories, their clinical laboratory data, and a 
wide variety of other information. 
 
Clinical Decision Support (CDS) – provides clinicians, staff, patients, and others involved in the 
care with knowledge and patient-specific information to improve health and health care. 
 
Computerized Physician Order Entry (CPOE) – providers use a computer application to enter 
and send treatment instructions such as laboratory and medication orders. 
 
Pharmacogenomics (PGx) – study of how genes affect an individual’s response to drugs. 
 
Adverse Drug Reaction (ADR) – the unwanted and undesired effects of a medication. 
 
Limitations 
 
 The collection, implementation, and utilization of pharmacogenomic data has started to 
increase, however, there are still many organizations that do not follow this practice. The 
limitation of the study is that only a small number of institutions have fully implemented 
pharmacogenomic data in their EHR system and are utilizing that data with their CDS system to 
make changes in prescribing practices at those institutions. The implementation of such system is 
also concentrated in large academic systems, which does not provide the full viewpoint of the 
impact of utilizing a pharmacogenomic CDS system with an EHR system. There are still some 
institutions that have not adopted a complete EHR system. There is limited data on the impact of 
the implementation of Pharmacogenomics data into EHR and CDS systems.   
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Chapter 2 
 
Review of Literature 
 
Introduction 
 
 Healthcare in the United States has seen drastic changes over the years. One major 
change that is seen at most institutions is the use of information technology. The growing use of 
information technology has led to the development of several branches in health informatics such 
as pharmacy informatics and nursing informatics. The advancements in informatics and 
information technology has increased the utilization of new technologies such as electronic 
health records (EHR) and computerized physician order entry (CPOE) system. The adoption of 
and EHR system has increased in healthcare institutions in the United States. These changes 
have helped institutions improve patient care.   
For years, there has been a view of a one size fits all model with drug therapy for 
patients. With the advent of new technology, there has been a push towards personalized 
medicine. The ultimate result of personalized medicine would be increased quality and safety of 
care for patients. This systemic literature review is an effort to determine the implementation of 
pharmacogenomics data into electronic health records at healthcare institutions across the United 
States and determine whether prescribing practices have changed as a result of such 
implementation. 
Method 
 The literature review was conducted using several electronic sources such as PubMed, 
Scopus, and the Web of Science. Various search terms were used to identify relevant articles 
such as electronic health records, electronic medical records, and pharmacogenomics. A Medical 
Subject Headings (MeSH) search was conducted on PubMed using “Electronic health records.” 
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The MeSH terms were then used to build a search query, which yielded 34,391 articles. Another 
MeSH term search was conducted using the search terms “Medical Records System.” The results 
of the MeSH search were utilized to build a search query, which yielded 38,856. The above 
queries were combined together, which resulted in 20,144 articles. A MeSH search was 
conducted utilizing the term pharmacogenomics, and a search query was conducted utilizing the 
MeSH search results, which generated 26,748 articles. The results of the “Electronic Health 
Records,” “Medical Records System,” and “Pharmacogenomics” were combined to refine the 
search query, which resulted in 113 articles. The search was further limited to articles from the 
last 5 years, which narrowed the search to 65 articles. The same search query that was used in 
PubMed was utilized in Scopus and Web of Science, which resulted in 81 and 1 articles 
respectively. The total number of articles obtained from all three databases was 147 articles. 
After duplicates were removed, there were a total of 140 articles remaining for this review.  
 Another search MeSH search was conducted utilizing the term Clinical Decision Support, 
which was then used to build a search query, which resulted in 52,968 articles. This search query 
was combined with the previous queries, and it resulted in 51 articles. The search was then 
limited to articles from the last 5 years, which narrowed the search to 46 articles. The literature 
articles utilized in this review discuss the implementation of pharmacogenomic information in 
electronic health records and clinical decision support systems. in hospitals in the United States. 
Inclusion Criteria  
The article was included if it contained any of the following: 
1. Published in the last 5 years 
2. The article discussed utilizing pharmacogenomic data by implementing them into EHR 
and CDS system 
3. Article was published in the United States 
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Exclusion Criteria  
The article was excluded if it contained any of the following: 
1. The article was not a research article such as an editorial, case study, comment piece, and 
book section 
2. The article was published in a language other than English 
3. The article was published outside of the United States 
 
Eligibility of the articles was initially determined based on the title and abstracts. Once it was 
determined that the article met the inclusion criteria, full text articles were retrieved and studied 
to determine their relevance. This search generated 10 articles that were relevant to the topic of 
this literature review. Similar steps were followed to narrow the results of the second search. 
Duplicates that were a part of the previous queries were removed and the remaining articles were 
analyzed for this literature review, which resulted in a total of 3 additional articles because 
majority of the articles were duplicates from the previous search query. Articles were included 
and excluded if they did not meet the above inclusion criteria (Figure 1, Appendix 1). After 
careful review, the search was narrowed to 13 articles (Table 1). 
Population Studied 
 The articles chosen for this review had different types of populations that were studied. 
Some articles studied prescribers and their response to employing pharmacogenomic information 
with CDS while prescribing medications. For example, Devine et al presented clinicians with 
hypothetical clinical scenarios and studied their prescribing practice based on the 
pharmacogenomic data that was presented (Devine et al., 2014). Some articles studied the EHR 
and CDS systems that presented the pharmacogenomic data to determine challenges in 
implementing such systems and find potential solutions to tackle these challenges (Rosenman, 
2017). 
Survey Method 
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 There were many different survey methods utilized in the articles that were a part of this 
review. Some studies utilized hypothetical clinical case scenarios to determine response of 
prescribers to gene-drug pair that might require dosage adjustment. Some studies collected data 
over a period of time to determine how many CDS alerts were generated and if those alerts led 
clinicians to make changes in their prescribing practice. For example, Ubanyionwu et al studied 
prescriber’s response to CDS alerts that were designed to prompt testing for a TPMT genetic 
variance. Some studies sent surveys to providers to evaluate prescriber perspective on the 
implementation and usefulness of pharmacogenomic testing in clinical practice. 
Table 1: Comparison of Reviewed Studies 
Author, 
Year 
Objective, Participant Study Method Results 
Ubanyionwu 
et al. (2018) 
Single-center, 
retrospective, chart-
review 
Prescriber’s response 
Clinical Decision Support 
(CDS) alert designed to 
prompt TPMT testing 
9-month study period: 500 CDS alerts 
generated: TPMT testing ordered in 
20% of the cases; TPMT phenotyping 
not ordered in 80% of the cases 
Caraballo et 
al. (2017) 
Overcome challenges 
of PGx implementation 
with comprehensive 
and systematic 
implementation model 
Development and 
implementation of PGx 
organized into 8 
interdependent components; 
aspects of implementation 
were assessed 
18 drug-gene drug interactions 
implemented in EHR; complete 
adherence to the model; 
implementation impacted 
approximately 1,247 providers and 
3,788 patients 
Hicks et al. 
(2016) 
Development of 
pharmacist-managed 
pharmacogenomic 
services 
CPIC guidelines for various 
drug-gene pairs were 
integrated into patient care; 
custom rules and alerts were 
developed and deployed to 
EHR for providing 
pharmacogenomic decision 
support 
Integrating just 3 genes over a 3-
month period identified 17 patients at 
risk for severe adverse reactions, and 
resulted in reduction of 
pharmacotherapy to reduce the risk of 
adverse events 
Manzi et al. 
(2016) 
Implementation of a 
comprehensive clinical 
PGx service 
CDS for medication ordering 
and dispensing driven by 
documented PGx variant 
status in EHR; 
CDS provided guidance to providers 
for 31 patients with actionable PGx 
variants 
St Sauver et 
al. (2016) 
Provider response to 
PGx CDS alerts 
integration into EHR 
159 clinicians were sent an 
e-mail survey to understand 
perspectives on the 
implementation and use of 
PGx testing in clinical 
practice 
Survey response rate = 57%; 52% did 
not expect to use or did not know 
whether they would use PGx 
information in future prescribing 
practices; 53% of the clinicians felt 
alerts were confusing, irritating, 
frustrating, or difficult to find 
additional information; 30% of the 
providers that received a CDS alert 
changed their prescription to an 
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alternative medication 
Nishimura et 
al. (2016) 
Create proof-of-concept 
decision support alert 
system generated from 
PGx incidental findings 
Decision support rules using 
discrete, machine-readable 
incidental finding results 
programmed into an EHR 
system 
Alerts for 48 pharmacogenomic 
variants created; 94 participants 
enrolled in the study, with 49 
participants having one or more PGx 
variant identified 
Overby et al. 
(2015) 
Determine clinical 
impact of CDS system 
embedded in EHR to 
deliver PGx 
information to 
physicians 
22 physicians participated in 
the study; physicians 
performed prescribing tasks 
utilizing simulated clinical 
case scenarios  
83% of physicians saw an advantage 
using PGx-CDS at the start of the 
study and 94% at the end of the study;  
Nishimura et 
al. (2015) 
Determine if physicians 
find CDS alerts for 
PGx drug-gene 
interactions useful and 
assess perceptions of 
usability 
52 physicians participated in 
an online simulation and 
questionnaire involving a 
prototype alert for 
clopidogrel and CYP2C19 
4% of participants said they would 
override alert; 92% agreed alerts were 
useful; 87% found visual interface 
appropriate; 91% felt timing of alert 
appropriate; and 75% unfamiliar with 
specific drug-gene interaction; 80% 
preferred ability to order the 
recommended medication within the 
alert 
Devine et al. 
(2014) 
Evaluate a CPOE 
system with PGx-CDS 
alerts in a simulated 
environment 
Presented 7 cardiologists and 
3 oncologists with five 
hypothetical clinical case 
scenarios 
Participants considered PGx 
information important for prescribing 
decisions, but the information needs 
to be presented in a relevant and 
useful manner 
Rosenman et 
al. (2017) 
Describe challenges 
and potential solutions  
of implementing 
programs to support 
precision medicine 
Descriptive case study of 
implementation of 
pharmacogenomics program 
in an urban safety-net 
hospital and its outpatient 
clinics 
There is strong potential for PGx to 
improve health and heath care and be 
cost-effective, but there are many 
challenges that need to be addressed 
when bringing PGx into wider use 
Caraballo et 
al. (2015) 
Clinical decision 
support to implement 
CYP2D6 Drug-Gene 
Interaction 
Developed CDS rules to alert 
prescribers based on PGx 
results for CYP2D6 and 
documentation of phenotype 
and genotypes in the EHR  
Total of 206 events triggered over 
study period; 45% were unreadable; 
implementation of CDS integrated in 
EHR is feasible, but significant 
challenges are present 
Danahey et 
al. (2017) 
Build and design a 
user-friendly Genomic 
Prescribing System 
(GPS) 
PGx information was 
collected and external data 
sets were integrated to build 
the Genomic Prescribing 
System 
The GPS had 257 CDS encompassing 
112 genetic variants, 42 genes, and 46 
PGx-actionable drugs; system had 
nearly 2000 logins in 43 months since 
inception; deployment of GPS 
provided a tool that allowed point of 
care genomic delivery with high 
usability 
O’Donnell et 
al. (2017) 
Study the influence of 
PGx alerts on 
prescribing behaviors 
Seventeen providers from 8 
different medicine primary 
care and subspecialty clinics 
participated in the study 
2279 outpatient encounters were 
analyzed; high PGx risk medications 
were changed more often than 
medications lacking PGx information; 
medications with cautionary PGx 
information also changed more 
frequently; PGx information improved 
prescribing in patterns aimed at 
reducing patient risk 
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Chapter 3 
Results 
 The healthcare field has experienced numerous technological advances, which have 
helped improve patient care. The introduction and implementation of EHR systems and CDS 
systems have helped improve how clinicians provide care to their patients. Scientific discoveries 
in the pharmacogenomic fields have helped scientists understand how medications may effect 
patients differently. Implementing pharmacogenomic information into EHR and CDS systems 
could potentially help providers appropriately prescribe certain medications and reduce the risk 
of adverse events. The articles from this literature review discuss various topics related to 
pharmacogenomics and EHR and CDS systems. 
 Ubanyionwu et al studied prescribers’ responses to CDS alerts designed to prompt S-
methyltransferase (TPMT), which is an enzyme, genetic testing. There are several medications, 
such as azathioprine, mercaptopurine, and thioguanine, that are inactivated by TPMT. Low 
TPMT activity can lead to an accumulation of the active metabolites of these medications and 
increased risk of toxicities. This is the reason scientists are advocating for preemptive TPMT 
genetic testing before starting therapy with these agents. The authors conducted a single-center, 
retrospective chart review to evaluate prescriber response to the TPMT genetic testing alert. The 
healthcare institution had implemented CDS alerts that were designed to fire when  a prescriber 
ordered thiopurine. The studied found that during the study period, 500 CDS alerts were 
generated, and TPMT testing was ordered in only 20% of the cases; in 80% of the cases, testing 
was not ordered. The study found that a large number of alerts were neglected due to poor 
alerting accuracy and alert fatigue. The authors also discovered that there was limited use of 
online thiopurine doses by prescribers. The authors indicated that pharmacogenomic CDS 
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enables clinicians to identify patients at risk for adverse reactions due to medications such as 
thiopurine. This will help improve prescribing practices in the future. 
 A study by Caraballo et al developed a study to overcome technical and clinical 
challenges associated with implementing pharmacogenomic data. The investigators organized 
the implementation into eight independent components addressing “resources, governance, 
clinical practice, education, testing, knowledge translation, clinical decision support (CDS), and 
maintenance” (Caraballo et al., 2017). This study was conducted at the Mayo Clinic, which is a 
large academic medical center. During the study period, the researchers reviewed 21 specific 
drug-gene interactions, and implemented 18 of those into the EHR system as pharmacogenomic-
CDS interventions. They found complete adherence to the model, but variable production and 
delay time. The researchers observed prescriber resistance to provide approval due to limited 
literature to support implement pharmacogenomic testing. The study had a total of 1,247 
providers that interacted with the pharmacogenomic CDS system during the study period, and 
they observed that interventions were triggered for 3,788 unique patients. They also implemented 
education resources to complement the drug-gene interactions to provide clinicians additional 
resources. The authors concluded that a comprehensive model can support pharmacogenomic 
implementation, but there are challenges that need to be addressed and overcome to expand the 
usage of pharmacogenomics data. 
 Hicks et al described a pharmacist-managed pharmacogenomic services within a large 
health system. The investigators used the Clinical Pharmacogenetics Implementation Consortium 
(CPIC) guidelines for several drug-gene pairs and developed custom rules and alerts that were 
implemented into an EHR system to provide pharmacogenomic CDS. The study was conducted 
at the Cleveland Clinic Health System. They found that integrating 3 gene-drug pairs over a 3-
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month study period, they identified 17 patients at risk for severe adverse reactions. The 
investigators found that clinicians recommended a pharmacogenomics consultation service to 
address questions that are not gathered by CDS or data-mining services. These alerts 
subsequently resulted in a change in the prescribing of the medication therapy to help reduce the 
risk of adverse events in patients. 
 A study was conducted to outline the implementation of a comprehensive clinical 
pharmacogenomics service in a pediatric hospital and the integration of CDS in the EHR. Manzi 
et al describe how clinical decision support based on documented pharmacogenomic variant 
status in EHR plays a role in ordering and dispensing medication. They found that CDS rules 
built in the EHR provided guidance to healthcare providers for 31 patients with actionable 
pharmacogenomic variant. The researchers concluded that if pharmacogenomic data is 
incorporated into CDS properly, there is potential to impact incidence of adverse drug events. 
 A study by St Sauver et al was conducted to survey primary care clinicians’ response to 
integration of pharmacogenomic CDS alerts in the EHR. The investigators sent surveys to 
clinicians in the Mayo Clinic Primary Care Practice. The goals of the surveys was to analyze the 
clinicians’ perception of implementation of pharmacogenomics and whether they thought this 
would be useful in their practice. From the survey, they found that 52% of the providers did not 
expect or did not know whether they would use pharmacogenomic information in future 
prescribing practices. They also found that approximately 53% of the clinicians felt that the 
alerts were confusing, frustrating, irritating, and it was not easy to find additional information 
regarding the alert. Investigators reported that only 30% of the clinicians made a change in their 
prescribing practice due to a CDS alert. The authors concluded that there was lack of clinician 
comfort with integration of pharmacogenomic data into primary care and the pharmacogenomic 
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CDS systems need to be user-friendly. 
 Nishimura et al set out to create a CDS system that incorporates pharmacogenomic data. 
The investigators programmed CDS rules using machine-readable incidental findings into an 
EHR system. They created alerts for 48 actionable pharmacogenomic variants in 11 genes. The 
authors concluded that incidental findings could possibly be used to create CDS alerts, however, 
tremendous resources are required to ensure that alerts are consistent with updated 
pharmacogenomic literature. 
 Another study led by Nishimura with another group studied physician opinions on CDS 
alerts for pharmacogenomic drug-gene interaction alerts and whether those alerts are useful to 
them in their practice. They invited 52 physicians to participate in a simulation and a survey 
which involved a CDS alert for clopidogrel and CYP2C10 drug-gene interaction. They found 
that only 4% of the participants reported that they would override the alert. Approximately 92% 
of the participants felt that the alerts were useful. The researchers concluded that many 
physicians were open to pharmacogenomic CDS alerts, especially when they are user-friendly 
and placed appropriately in the prescribing process. 
 Overby et al developed a study to investigate the clinical impact of using a CDS system 
embedded in an EHR system to provide pharmacogenomic information to prescribers. The 
investigators recruited 22 physicians to participate in the study. The study found that 
approximately 83% of the participants found an advantage to using pharmacogenomic CDS 
system before the study, and that number increased to 94% at the end of the study. The 
researchers concluded that the pharmacogenomic CDS system needs to be user-friendly and 
there needs to be a focus on content delivery, content, and tailoring to prescriber characteristics. 
 A computerized physician order entry (CPOE) system with pharmacogenomic CDS alerts 
 19 
was evaluated by Devine et al. They recruited a group of cardiologists and oncologists and 
presented them with five hypothetical clinical case scenarios. The scenarios included a drug-gene 
pair that would require dosage adjustment consideration. The participants reported that 
pharmacogenomic data is important for prescribing decisions, however, the information needs to 
be shown in a useful manner. The authors concluded that prescribers are more likely to 
incorporate pharmacogenomic CDS when the information is presented in a user-friendly manner. 
 Rosenman et al explored the challenges associated with implementing new programs to 
support precision medicine. In this descriptive study, the authors investigated the process of 
implementing a pharmacogenomic program at a hospital and its outpatient clinics. The study 
included 14 genes and 27 medications. The researchers discovered that some of the challenges 
included clinician education and changes in standards of care, integrating pharmacogenomics 
into EHR systems, and patient education and participation in the decision-making process. The 
authors drew a conclusion that pharmacogenomics CDS has strong potential to improv health 
care, but the challenges that are present need to be tackled to be able to utilize this valuable tool. 
 Caraballo et al published a brief article in which they integrated CDS alerts in an EHR 
system for the gene encoding CYP2D6. They created a series of CDS rules to alerts providers 
based on the results of pharmacogenomic testing for CYP2D6 and the documented genotypes 
and phenotypes in the EHR. The CDS alerts fired for high or low activity of this gene. The alerts 
also linked providers to additional pharmacogenomic education and alternative treatment options 
if there were any available. During the study period, there were a total of 206 events that were 
triggered by the CPOE system. They found that approximately 75% of the alerts were displayed 
due to increased activity and approximately 25% due to decreased activity. They also found that 
some alerts were displayed multiple times for the same drug/patient/provider interaction. The 
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authors found that integrating CDS alerts into an EHR system is plausible, however, there 
significant challenges. Clinicians need to be provided with education to understand these alerts 
and prevent unnecessary and repetitive alerts. 
 A group of investigators, Danahey et al, built and designed a genomic prescribing system. 
The investigators documented that a big implementation challenge lies in incorporating clinically 
actionable genomic data in the EHR system. The goal of this project was to build a system that 
was user-friendly and allowed the system to incorporate complex genomic data. They had 
incorporated 257 CDS alerts, which included 112 genetic variants, 42 genes, and 46 
pharmacogenomic actionable drugs. The CDS alerts presented users with three different colors to 
denote the risk for each genomic result. The system had 2000 logins in 43 months. The authors 
concluded that a user-friendly genomic prescribing tool allowed enabled point-of-care genomic 
delivery with high rate of use. 
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Chapter 4 
Discussion 
 The articles that were selected for this review touched upon various topics related to 
pharmacogenomics implementation into EHR and CDS systems. Many of the articles discussed 
implementing a new pharmacogenomic CDS system within an EHR and evaluating clinician 
interaction with these systems. The studies revealed that they were able to implement these 
systems, however, they learned that there are many challenges that came to light during this 
process. They needed to find solutions for these complications to make the system better. 
 There were many challenges that were reported in this studies. The common issues that 
came up in these studies were lack of prescriber knowledge of pharmacogenomics and how it 
would impact their prescribing practices. Some prescribers were able to see benefits in their 
prescribing practice after they had participated in the study. The studies also found that users of 
these systems wanted a user-friendly interface that provided the necessary information in the 
prescribing process. The participants also wanted the system to provide them with additional 
information regarding the specific alert and alternative medication if it is available. 
 The studies noted that there is potential for pharmacogenomics to decrease adverse drug 
reactions and improve drug efficacy, however, there are several challenges that have kept the 
incorporation rate slow. The challenges include reimbursement for genetic testing, developing an 
infrastructure and standardized process to store, access, and interpret genomic data, and clinician 
hesitation regarding the clinical and financial benefits of pharmacogenomics guided treatment 
regimen. There is concern that the current EHR and CDS tools may not be able to handle the 
influx of genomic data that is anticipated in the future, which means that additional infrastructure 
will be required. A comprehensive strategy that incorporates all aspects of pharmacogenomic 
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driven medicine, starting from the laboratory to data migration and clinical involvement to 
multidisciplinary governance is required to tackle this challenge.  
 Institutions are starting to realize the benefits of implementing pharmacogenomic CDS 
into their EHR system. They have learned that they can improve patient care if they incorporate 
such system. There are challenges that need to be overcome when implementing these systems. 
There are a lack of studies that evaluate the impact of pharmacogenomic CDS systems and the 
true clinical impact is unclear. Many of the studies that are published only provide a short-term 
impact of the pharmacogenomic CDS. Majority of the pharmacogenomic implementations are 
currently limited to large academic medical centers. There is still a need for clinician-friendly 
pharmacogenomic CDS systems and more research needs to be conducted on this topic.  
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Chapter 5 
Conclusion and Recommendations 
 Medical science is advancing at rapid pace and many new technologies are being utilized 
to provide better care for patients. Numerous institutions have made extensive efforts to 
implement pharmacogenomic CDS in clinical practice, however, they have faced many 
challenges along the way, and the true clinical impact is unclear. The majority of the current 
pharmacogenomic implementations have occurred in academic medical centers, which does not 
provide a clear view of the impact of such system in other traditional healthcare institutions. If 
institutions are able to implement user-friendly pharmacogenomic CDS integrated into an EHR 
system, it has the potential to support pharmacogenomic driven medicine, which will help reduce 
adverse drug reactions and improve therapeutic efficacy of the treatment regimen a patient 
receives. There is a lack of published literature on this topic. 
 This literature search was extensive; however, another literature search should be 
conducted to ensure that all studies that are related to this article are identified. Other search 
terms that could potentially be incorporated in the search are computerized physician order entry 
system and health information technology. Researchers need to conduct extensive studies to truly 
identify the clinical impact of implementing pharmacogenomic CDS integrated into an EHR 
system. These types of studies will help discover the true benefits of pharmacogenomic CDS and 
aid in brining changes to the current standard of patient care.  
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Appendix 1 
 
Figure 1: Initial search query which included the search terms electronic health records, medical records system, and 
pharmacogenomics. 
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Figure 2: Second search query which included the search terms electronic health records, medical records system, and 
pharmacogenomics, clinical decision support. 
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Appendix 2 
Database Search Query Results 
PubMed 
 
(((("Electronic Health Records"[Mesh] OR "Electronic Health Records" OR 
"Electronic Health Record" OR "Electronic Medical Records" OR 
"Electronic Medical Record" OR "Computerized Medical Record" OR 
"Computerized Medical Records")) AND ("Medical Records Systems, 
Computerized"[Mesh] OR "Medical Record Systems" OR "Computerized 
Patient Medical Records" OR "Automated Medical Records System" OR 
"Automated Medical Record System" OR "Computerized Medical Record 
System" OR "Computerized Medical Records System" OR "Computerized 
Medical Record Systems" OR "Computerized Medical Records Systems" 
OR "Automated Medical Record System" OR "Automated Medical Record 
Systems"))) AND ("Pharmacogenetics"[Mesh] OR "Pharmacogenetics" OR 
"Pharmacogenomics" OR "Pharmacogenomic") 
65 
((((((("Medical Records Systems, Computerized"[Mesh] OR "Medical 
Records Systems, Computerized" OR "Automated Medical Records 
System" OR "Medical Record System, Automated" OR "Medical Record 
Systems, Automated" OR "Medical Records System, Automated" OR 
"Medical Records Systems, Automated" OR "Automated Medical Records 
Systems" OR "Computerized Medical Record System" OR "Computerized 
Medical Record Systems" OR "Computerized Medical Records System" OR 
"Medical Record System, Computerized" OR "Medical Record Systems, 
Computerized" OR "Medical Records System, Computerized" OR 
"Computerized Medical Records Systems" OR "Automated Medical Record 
System" OR "Automated Medical Record Systems"))) AND ("Electronic 
Health Records"[Mesh] OR "Electronic Health Records" OR "Electronic 
Medical Records" OR "Electronic Medical Record" OR "Medical Record, 
Electronic" OR "Medical Records, Electronic" OR "Record, Electronic 
Medical" OR "Records, Electronic Medical" OR "Electronic Health Record" 
OR "Health Record, Electronic" OR "Health Records, Electronic" OR 
"Record, Electronic Health" OR "Records, Electronic Health" OR "Medical 
Records, Computerized" OR "Medical Record, Computerized" OR 
"Computerized Medical Record" OR " Record, Computerized Medical" OR 
"Records, Computerized Medical" OR "Computerized Medical Records"))) 
AND ("Decision Support Systems, Clinical"[Mesh] OR "Decision Support 
Systems, Clinical" OR "Clinical Decision Support Systems" OR "Clinical 
Decision Support" OR "Clinical Decision Supports" OR "Decision 
Supports, Clinical" OR "Support, Clinical Decision" OR "Supports, Clinical 
Decision" OR "Decision, Support, Clinical"))) AND 
("Pharmacogenetics"[Mesh] OR "Pharmacogenetics" OR 
"Pharmacogenetic" OR "Pharmacogenomic" OR "Pharmacogenomics") 
31 
 
Scopus 
(((("Electronic Health Records" OR "Electronic Health Records" OR 
"Electronic Health Record" OR "Electronic Medical Records" OR 
81 
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"Electronic Medical Record" OR "Computerized Medical Record" OR 
"Computerized Medical Records")) AND ("Medical Records Systems, 
Computerized" OR "Medical Record Systems" OR "Computerized Patient 
Medical Records" OR "Automated Medical Records System" OR 
"Automated Medical Record System" OR "Computerized Medical Record 
System" OR "Computerized Medical Records System" OR "Computerized 
Medical Record Systems" OR "Computerized Medical Records Systems" 
OR "Automated Medical Record System" OR "Automated Medical Record 
Systems"))) AND ("Pharmacogenetics" OR "Pharmacogenetics" OR 
"Pharmacogenomics" OR "Pharmacogenomic") 
((((((("Medical Records Systems, Computerized" OR "Medical Records 
Systems, Computerized" OR "Automated Medical Records System" OR 
"Medical Record System, Automated" OR "Medical Record Systems, 
Automated" OR "Medical Records System, Automated" OR "Medical 
Records Systems, Automated" OR "Automated Medical Records Systems" 
OR "Computerized Medical Record System" OR "Computerized Medical 
Record Systems" OR "Computerized Medical Records System" OR 
"Medical Record System, Computerized" OR "Medical Record Systems, 
Computerized" OR "Medical Records System, Computerized" OR 
"Computerized Medical Records Systems" OR "Automated Medical Record 
System" OR "Automated Medical Record Systems"))) AND ("Electronic 
Health Records" OR "Electronic Health Records" OR "Electronic Medical 
Records" OR "Electronic Medical Record" OR "Medical Record, 
Electronic" OR "Medical Records, Electronic" OR "Record, Electronic 
Medical" OR "Records, Electronic Medical" OR "Electronic Health Record" 
OR "Health Record, Electronic" OR "Health Records, Electronic" OR 
"Record, Electronic Health" OR "Records, Electronic Health" OR "Medical 
Records, Computerized" OR "Medical Record, Computerized" OR 
"Computerized Medical Record" OR " Record, Computerized Medical" OR 
"Records, Computerized Medical" OR "Computerized Medical Records"))) 
AND ("Decision Support Systems, Clinical" OR "Decision Support 
Systems, Clinical" OR "Clinical Decision Support Systems" OR "Clinical 
Decision Support" OR "Clinical Decision Supports" OR "Decision 
Supports, Clinical" OR "Support, Clinical Decision" OR "Supports, Clinical 
Decision" OR "Decision, Support, Clinical"))) AND ("Pharmacogenetics" 
OR "Pharmacogenetics" OR "Pharmacogenetic" OR "Pharmacogenomic" 
OR "Pharmacogenomics") 
1 
 
Web of 
Science 
(((("Electronic Health Records" OR "Electronic Health Records" OR 
"Electronic Health Record" OR "Electronic Medical Records" OR 
"Electronic Medical Record" OR "Computerized Medical Record" OR 
"Computerized Medical Records")) AND ("Medical Records Systems, 
Computerized" OR "Medical Record Systems" OR "Computerized Patient 
Medical Records" OR "Automated Medical Records System" OR 
"Automated Medical Record System" OR "Computerized Medical Record 
System" OR "Computerized Medical Records System" OR "Computerized 
1 
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Medical Record Systems" OR "Computerized Medical Records Systems" 
OR "Automated Medical Record System" OR "Automated Medical Record 
Systems"))) AND ("Pharmacogenetics" OR "Pharmacogenetics" OR 
"Pharmacogenomics" OR "Pharmacogenomic") 
((((((("Medical Records Systems, Computerized" OR "Medical Records 
Systems, Computerized" OR "Automated Medical Records System" OR 
"Medical Record System, Automated" OR "Medical Record Systems, 
Automated" OR "Medical Records System, Automated" OR "Medical 
Records Systems, Automated" OR "Automated Medical Records Systems" 
OR "Computerized Medical Record System" OR "Computerized Medical 
Record Systems" OR "Computerized Medical Records System" OR 
"Medical Record System, Computerized" OR "Medical Record Systems, 
Computerized" OR "Medical Records System, Computerized" OR 
"Computerized Medical Records Systems" OR "Automated Medical Record 
System" OR "Automated Medical Record Systems"))) AND ("Electronic 
Health Records" OR "Electronic Health Records" OR "Electronic Medical 
Records" OR "Electronic Medical Record" OR "Medical Record, 
Electronic" OR "Medical Records, Electronic" OR "Record, Electronic 
Medical" OR "Records, Electronic Medical" OR "Electronic Health Record" 
OR "Health Record, Electronic" OR "Health Records, Electronic" OR 
"Record, Electronic Health" OR "Records, Electronic Health" OR "Medical 
Records, Computerized" OR "Medical Record, Computerized" OR 
"Computerized Medical Record" OR " Record, Computerized Medical" OR 
"Records, Computerized Medical" OR "Computerized Medical Records"))) 
AND ("Decision Support Systems, Clinical" OR "Decision Support 
Systems, Clinical" OR "Clinical Decision Support Systems" OR "Clinical 
Decision Support" OR "Clinical Decision Supports" OR "Decision 
Supports, Clinical" OR "Support, Clinical Decision" OR "Supports, Clinical 
Decision" OR "Decision, Support, Clinical"))) AND ("Pharmacogenetics" 
OR "Pharmacogenetics" OR "Pharmacogenetic" OR "Pharmacogenomic" 
OR "Pharmacogenomics") 
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